Lower adiponectin levels (MD -2.85) and higher visfatin levels (MD 2.99) were significantly associated with the occurrence of major adverse cardiovascular events in patients following acute myocardial infarction.
Meta-Analysis (n=707)
Are circulating adipokine levels, particularly adiponectin and visfatin, associated with the occurrence of major adverse cardiovascular events (MACE) during follow-up in patients with acute myocardial infarction (AMI)?
Lower adiponectin and higher visfatin levels are associated with an increased risk of major adverse cardiovascular events following acute myocardial infarction, suggesting their potential utility as prognostic biomarkers.
Mean Difference: -2.85 (95% CI -5.42–-0.27)
p-value: p=0.03
Abstract Background Major adverse cardiovascular events (MACEs) remain a leading cause of poor prognosis following acute myocardial infarction (AMI). Emerging evidence suggests that adipose tissue-derived adipokines may provide additional information on cardiometabolic risk beyond conventional anthropometric measures. This systematic review and meta-analysis aimed to evaluate the association between circulating adipokines, specifically adiponectin and visfatin, and the occurrence of MACE among patients with AMI. Methods A systematic search of PubMed/MEDLINE, Scopus, and Cochrane Library was performed from inception to identify cohort studies reporting adiponectin or visfatin levels in adult AMI patients with and without MACE during follow-up. Pooled mean differences (MD) with 95% confidence intervals (CI) were calculated. Results Five cohort studies ( n = 707 AMI patients) conducted across China, Taiwan, Japan, and Poland, with follow-up durations ranging from 2 to 43 months, were included. Adiponectin levels were lower in MACE patients (MD=-2.85 95% CI -5.42 to -0.27, p = 0.03; I 2 = 94%), while visfatin levels were significantly higher in the MACE group (MD = 2.99 95% CI 1.51 to 4.47, p < 0.0001; I 2= 0%). Conclusion Lower adiponectin and higher visfatin levels are associated with MACE occurrences in AMI patients, whereas BMI did not demonstrate significant discriminatory value.
Nadira et al. (Fri,) conducted a meta-analysis in Acute myocardial infarction (AMI) (n=707). Circulating adiponectin and visfatin levels vs. AMI patients without MACE was evaluated on Difference in adiponectin levels between MACE and non-MACE groups (MD -2.85, 95% CI -5.42 to -0.27, p=0.03). Lower adiponectin levels (MD -2.85) and higher visfatin levels (MD 2.99) were significantly associated with the occurrence of major adverse cardiovascular events in patients following acute myocardial infarction.